Navigation Links
GenturaDx to Host Poster Presentation at Association for Molecular Pathology 2011 Annual Meeting
Date:11/14/2011

HAYWARD, Calif., Nov. 14, 2011 /PRNewswire/ -- GenturaDx today announced that it will present data from alpha studies performed in Q2 2011 at the Association for Molecular Pathology 2011 Annual Meeting on Friday, November 18 from 2:15 p.m. to 3:30 p.m. Poster number ID 23 titled "Comparison Of Assay Performance Between Cell Culture And A Rapid Automated Molecular Test For HSV Typing Of Clinical Samples" will address the capability of the GenturaDx IDbox™ System to detect HSV 1/2 as compared with non-molecular methods. Lead author Nathalie Visomblin, Chief Scientific Officer/Co-Founder Dr. Jesus Ching, and Senior Vice President of Research and Development Dr. Geoff McKinley will be on hand to answer questions.

The GenturaDx IDbox™ System will be on display at booth 721. GenturaDx's fully automated molecular diagnostics platform, the IDbox™ System and its initial HSV 1/2 assay, are currently in beta testing with clinical trials beginning in 2012. The IDbox™ System is a compact, fully integrated system that can handle multiple sample types and assay chemistry options. With a broad menu of infectious disease tests and a true press play and walk away technology, the IDbox™ System will be the first to enable labs to meet both increasing clinical demand for molecular testing while maximizing laboratory efficiency.

About GenturaDx

GenturaDx is a molecular diagnostic company focused on making high-performance molecular diagnostics both affordable and practical for any laboratory to perform.  The company is developing a fully integrated, automated instrument that conducts testing using a single-use cassette. This platform will make rapid, high-quality molecular diagnostics accessible to hospitals and patients worldwide – circumventing long-standing barriers of costs, automation and performance. GenturaDx's compact, self-contained platform incorporates sample preparation with proprietary, real-time
'/>"/>

SOURCE GenturaDx
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. GenturaDx Appoints Senior Vice President of Research & Development
2. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
3. Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium
4. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
5. Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
6. CNS Response, Inc. Provides Review of Poster Session Delivered at the American Psychiatric Association 161st Annual Meeting
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
9. Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
10. PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009
11. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , October 30, 2014 ... has announced the addition of the  "Process Validation ... to their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... Science and Risk Based Approach to Process Validation ... Risk Management FDA Process Validation Guidance ...
(Date:10/31/2014)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announces ... Pharmaceuticals, Third Quarter 2014 Financial Results and Highlights Conference ... ET / 8:30 a.m. PTWhere: , www.isispharm.com ... onto our website listed above. If you are unable ... the webcast will be available for a limited time ...
(Date:10/31/2014)...  AbbVie (NYSE: ABBV ) today ... Sept. 30, 2014. "Our third-quarter ... with double-digit growth from HUMIRA and several other ... percent in the quarter excluding lipids," said Richard ...  "We exceeded our outlook for the quarter and ...
Breaking Medicine Technology:Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 3AbbVie Reports Third-Quarter 2014 Financial Results 2AbbVie Reports Third-Quarter 2014 Financial Results 3AbbVie Reports Third-Quarter 2014 Financial Results 4AbbVie Reports Third-Quarter 2014 Financial Results 5AbbVie Reports Third-Quarter 2014 Financial Results 6AbbVie Reports Third-Quarter 2014 Financial Results 7AbbVie Reports Third-Quarter 2014 Financial Results 8AbbVie Reports Third-Quarter 2014 Financial Results 9AbbVie Reports Third-Quarter 2014 Financial Results 10AbbVie Reports Third-Quarter 2014 Financial Results 11AbbVie Reports Third-Quarter 2014 Financial Results 12AbbVie Reports Third-Quarter 2014 Financial Results 13AbbVie Reports Third-Quarter 2014 Financial Results 14AbbVie Reports Third-Quarter 2014 Financial Results 15AbbVie Reports Third-Quarter 2014 Financial Results 16AbbVie Reports Third-Quarter 2014 Financial Results 17AbbVie Reports Third-Quarter 2014 Financial Results 18AbbVie Reports Third-Quarter 2014 Financial Results 19AbbVie Reports Third-Quarter 2014 Financial Results 20AbbVie Reports Third-Quarter 2014 Financial Results 21AbbVie Reports Third-Quarter 2014 Financial Results 22AbbVie Reports Third-Quarter 2014 Financial Results 23AbbVie Reports Third-Quarter 2014 Financial Results 24
... many, clinical studies are few, NEW YORK, ... revealed that a limited amount of clinical research ... anti-aging,products. The study is published in the July/August ... peer-reviewed journal of the,American Society for Aesthetic Plastic ...
... (Amex: IMM ) commented today on a ... group of researchers at the National Cancer Institute,on ... enzyme involved in the DNA,repair process (see Note ... proprietary, orally bioavailable prodrug, pafuramidine. Of,interest is furamidine,s ...
Cached Medicine Technology:OTC Anti-Aging Products: Hype or Hope? 2Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 2Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 3
(Date:10/31/2014)... Oct. 30, 2014 (HealthDay News) -- A comparison of ... surgery found that laparoscopic gastric bypass helped patients shed ... a higher risk of short-term complications and long-term hospitalizations. ... the small intestine, so your body does not absorb ... the National Institutes of Health. Gastric banding is a ...
(Date:10/31/2014)... HealthDay Reporter THURSDAY, Oct. 30, ... the risk of broken bones and injured joints, a new study ... among 7 percent of people who had an eczema flare-up in ... and 0.6 percent had an injury that caused a limitation of ... skin condition had more than double the risk of having had ...
(Date:10/30/2014)... could one day provide new treatments for injuries and ... ligaments. , Cartilage, for example, is a hard material ... to work smoothly. UC Davis biomedical engineers, exploring ways ... strong outside the body, report new developments this week ... of Sciences . , "The problem with engineered tissue ...
(Date:10/30/2014)... by NIH grantees predicts that women must take the ... vaginal sex, whereas just two doses per week can ... finding helps explain why two large clinical trials testing ... show efficacy. Participants in the VOICE and ... antiretroviral) for HIV prevention were counseled to take one ...
(Date:10/30/2014)... NC (PRWEB) October 30, 2014 Don ... commercial, and health insurance plans for North Carolina residents, ... satellite office in Burlington’s Holly Hill Mall. The new ... with agents already helping customers through all facets of ... purchase. , Allred Insurance spokesman Scott Allred couldn’t be ...
Breaking Medicine News(10 mins):Health News:Study Compares 2 Common Weight-Loss Surgeries 2Health News:Study Compares 2 Common Weight-Loss Surgeries 3Health News:Eczema Tied to Bone Fracture Risk in Study 2Health News:Making lab-grown tissues stronger 2Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2Health News:Allred Insurance Satellite Office Grand Opening 2
... Demonstrate Deepening Relationship , Between Edwards and Primary Sponsor ... off its first year as primary sponsor of Carl ... big way with the launch of its latest television ... to air during the national broadcast of the Feb. ...
... Prevent Preterm BirthWHITE PLAINS, N.Y., Feb. 11 ... may cause preterm labor in some women, investigate ... contractions and an early birth, and look at ... environmental risk factors for prematurity.The work of seven ...
... and St George,s, University of London measured recent exposure to ... British Regional Heart Study by measuring the levels of cotinine ... time points 20 years apart. A blood cotinine level above ... of a heart attack (2), and other studies have suggested ...
... Results of a recent study conducted by researchers ... show that cognitive functioning abilities drop as average blood ... , The study appears in this month,s issue of ... Diabetes (MIND) study, a sub-study of the Action to ...
... French . , Montreal, February 11th, 2009 ... the nutrients the tumours receive through the blood. The team ... McGill University Health Centre (MUHC) at the Montreal Children,s Hospital, ... a new mechanism that tumours use to stimulate the growth ...
... world,s first phase one FDA-approved clinical trial using adult ... conducted by a team of University of Louisville ... with advanced heart disease who already are undergoing bypass ... trial, which uses adult stem cells taken from the ...
Cached Medicine News:Health News:New Ads Provide Glimpse Into Unique Friendship Between Aflac Duck and Carl Edwards 2Health News:New Ads Provide Glimpse Into Unique Friendship Between Aflac Duck and Carl Edwards 3Health News:New Ads Provide Glimpse Into Unique Friendship Between Aflac Duck and Carl Edwards 4Health News:March of Dimes Provides $2.7 Million in New Funding For Preterm Birth Research 2Health News:March of Dimes Provides $2.7 Million in New Funding For Preterm Birth Research 3Health News:Smokers putting their loved ones at risk of heart attacks 2Health News:Higher blood sugar levels linked to lower brain function in diabetics, study shows 2Health News:Innovative method to starve tumors 2Health News:World's First Cardiac Adult Stem Cell Trial to Take Place in Louisville 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: